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Background Cardiac haemangiomas are extremely rare tumours with equivocal surgical outcomes. Haemangiomas appearing on
other sites of the body have been successfully treated with oral propranolol. To the best of our knowledge, such
treatment has not been tried to date for cardiac location of haemangiomas.
...................................................................................................................................................................................................
Case summary We report two cases of neonatal cardiac haemangiomas, and we describe their presentation and characteristics, as
well as how these were successfully treated with oral propranolol, with complete regression of the tumours within
the 1st year of life.
...................................................................................................................................................................................................
Discussion Despite the rarity of cardiac haemangiomas, their presentation and complications could be dramatic with side-
effects spanning from intracardiac space occupying phenomena to Kasabach–Merritt syndrome. Propranolol ther-
apy, having been established for long now in the treatment of skin haemangiomas, should also be considered in
cases of cardiac haemangiomas, particularly in the neonatal and infantile population.
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Introduction
Cardiac haemangiomas are extremely rare tumours with equivocal
surgical outcomes.1 Haemangiomas appearing on other sites of the
body, predominantly the skin, have over the last 10 years been suc-
cessfully treated with oral propranolol which has revolutionized their
treatment and has demonstrated a very good safety profile.2 To the
best of our knowledge, such treatment has not been tried to date for
cardiac location of haemangiomas.
We report two cases of neonatal cardiac haemangiomas that were
successfully treated with oral propranolol, with complete regression
Learning points
• Neonatal/infantile cardiac haemangiomas may have similar
characteristics to cutaneous haemangiomas.
• Oral propranolol has an established safety profile for this age
group and a proved efficacy in treatment of cutaneous
haemangiomas.
• Oral propranolol was effective in treating cardiac haemangio-
mas in our two cases and thus, we believe that it should be
tried as a treatment option in similar cases.
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of the tumours, hence we propose trial of propranolol in cases of





A female infant was diagnosed antenatally by ultrasound at 34 weeks
of gestation with pericardial effusion that persisted and showed in-
crease but no tamponade. Due to this finding the foetus was delivered
by caesarean section at 37þ 2 weeks of gestation with a birthweight
of 2530 g. On examination her heart sounds were normal with no
murmurs and she had good volume pulses, with no respiratory dis-
tress or evidence of cardiac failure. Immediately, postnatally, the neo-
nate had thrombocytopenia with platelet count as low as 22 000,
haemorrhagic predisposition evident at venipuncture sites and
anaemia with Hb of 8 g/dL. She required several transfusions and was
treated with intravenous (IV) immunoglobulin for 2 days and IV meth-
ylprednisolone at 4 mg/kg/day for 4 days, starting at the 3rd day of life.
The pericardial effusion improved significantly and the neonate was
discharged home at 15 days of life but was readmitted with tachyp-
noea, thrombocytopenia (platelets 90 000) and anaemia (Hb 8.1 g/dL)
at 31 days of life. During this 2nd admission, a cardiac mass was
detected by transthoracic echocardiography surrounding the apex of
the left ventricle with obvious blood flow within it on colour Doppler
(Figure 1).The mass appeared to be increasing in size and so was the
pericardial effusion, despite treatment with corticosteroids. She had a
full workup for all causes of thrombocytopenia including endocrin-
ology tests, autoimmune tests, metabolic tests, bone marrow aspir-
ation, and biopsy, with no abnormal findings.
She was referred to our hospital at 45 days of life for magnetic res-
onance imaging (MRI) of the heart, tissue characterization of the mass
and further management. On admission her transthoracic echocar-
diogram showed a mass around 21  10 mm at the diaphragmatic
border surrounding the apex of the left ventricle (Figure 2). The mass
was very echogenic with no evidence of blood flow within it. The
mass’s echogenicity at that time resembled a large thrombus.
Significant accumulation of pericardial fluid was noted. Magnetic res-
onance imaging tissue characterization suggested that the mass was
consistent with haemangioma with thrombi within its crypts and
measured 26  16  10 mm (Figure 3). Thrombosis explained the
disappearance of flow within the haemangioma, that had been
observed initially and in combination with the thrombocytopenia and
anaemia, the diagnosis of Kasabach–Merritt syndrome was made.3
No other haemangiomas were found during examination by chest
computed tomography and abdominal ultrasound. The large pericar-
dial effusion was drained to prevent tamponade; the aspirated fluid
was blood-stained with Hb of 2 g/dL. It was decided to attempt treat-
ing the tumour with oral propranolol, starting at Day 48 of life, at a
dose that was gradually titrated up to 3 mg/kg/day in three divided
doses, along with a 2nd course of IV methylprednisolone at a dose of
1 mg/kg/day in two doses for 3 days. The response was immediate




Initial evaluation A female foetus was diagnosed with
pericardial effusion that persisted and
showed increase but no tamponade
at 34 weeks of gestation. A cardiac
mass was detected at 15 days of life.
Cardiac haemangioma was diagnosed
by magnetic resonance imaging (MRI)
and clinical features of Kasabach–
Merritt syndrome were seen at 45
days and propranolol was started




Reduction on the mass’ size was
observed
12 months Complete resolution was demonstrated
and propranolol was stopped
4 years of follow-up There has been no relapse
Case 2
Initial evaluation A female foetus was diagnosed with a
cardiac tumour in the right atrium at
a gestational age of 28 þ 5 weeks
2 months Cardiac haemangioma was diagnosed by
MRI and propranolol was started
1 month after
treatment




Complete resolution was demonstrated
9 months Propranolol was stopped
2 years of follow-up There has been no relapse
Figure 1 Case 1: cardiac mass depicted at the apex of the heart
with posterior tilt, demonstrating blood flow within it on an echo-
cardiogram performed at 31 days of life. The yellow stars are outlin-
ing the borders of the mass and the yellow arrow is indicating the

























































anaemia were noted, with no recurrence of the effusion. Propranolol
was continued at the same dose per kilogram. Interestingly, when
propranolol had to be withheld for 5 days, subsequently to an epi-
sode of septicaemia and haemodynamic instability, the tumour
started increasing again in size in its longitudinal diameter, and
expanded over the diaphragmatic border of the right ventricle with a
size of about 34 16 mm. Propranolol was restarted and the size of
the haemangioma eventually decreased to half of its original size with-
in 3 months. The tumour completely disappeared within a year
(Figure 4), when the decision was made for gradual discontinuation of
therapy at the age of 14 months. Weaning was done by reducing
from three doses per day to two doses per day for 1 week, then one
dose per day for another week and then half of the single dose for
the last week before stopping it completely. The child has been fol-
lowed-up for the past 4 years with transthoracic echocardiograms
regularly and there has been no relapse of the haemangioma or fur-
ther signs and symptoms of Kasabach–Merritt syndrome.
Case presentation 2
A 38-year-old female was routinely followed-up by ultrasound during
her 5th pregnancy when a foetal cardiac tumour was observed in the
right atrium at a gestational age of 28þ 5 weeks. Previous pregnan-
cies were uncomplicated. Foetal echocardiography confirmed an 11
 15 mm cardiac mass in the right atrium without haemodynamic
compromise (Figure 5). A female neonate was born by vaginal deliv-
ery at 38þ 6 weeks of gestation weighing 3400 g. The patient was im-
mediately transferred to the paediatric cardiac surgery intensive care
unit for follow-up. A series of transthoracic echocardiograms
Figure 2 Case 1: cardiac mass on echocardiogram at 45 days of
life measuring 10 21 mm.
Figure 3 Case 1: cardiac magnetic resonance imaging performed
on the same day (Figure 2) was acquired.
Figure 4 Case 1: echocardiogram at 1 year of age showing no
signs of residual haemangioma at the apex of the heart.
Figure 5 Case 2: foetal echocardiogram at 28þ 5 weeks of gesta-
tion demonstrating a cardiac mass in the right atrium measuring 11



























































































confirmed the prenatal diagnosis of a right atrial tumour originating
from the opening of the right atrial appendage and also demonstrated
increase of the tumour size during the 1st month of life, still with no
haemodynamic compromise. Mild pericardial effusion was noted
without inflow or outflow obstructions, arrhythmias or extracardiac
anomalies. The neonate remained asymptomatic with a completely
normal cardiovascular examination, and at the age of 2 months
underwent cardiac MRI; that showed a mass measuring 28 mm in
diameter, T1 isointense (Figure 6), T2 hyperintense, and highly vascu-
lar with inflow voids (Figure 7). In the 1st past perfusion images, strong
enhancement appeared in the arterial phase. In the contrast
enhanced images, the tumour was heterogenous (mostly strong en-
hancement), whilst it appeared isointense on the late-gad images.
The diagnosis of infantile cardiac haemangioma was therefore sus-
pected. No other haemangiomas were noted elsewhere. Oral pro-
pranolol was initiated at the age of 2 months and titrated to the dose
of 3 mg/kg/day divided in three doses. Regression of the tumour size
was noticed in consecutive transthoracic echocardiograms and finally
the tumour disappeared completely at the age of 8 months.
Propranolol was discontinued at the age of 9 months after normal
cardiac MRI (Figure 8). The patient has been followed-up for
24 months since by transthoracic echocardiography, with no signs of
relapse of the haemangioma.
Discussion
Infantile haemangiomas of the skin are not a rare finding with a preva-
lence of 4–5% in term neonates.4 However, as a cardiac tumour, hae-
mangiomas are a rare occurrence in children, described only in a few
case series. Given that the prevalence of cardiac tumours in children
in general is as low as 0.0017–0.28% in autopsy series,5,6 and the
prevalence of haemangiomas is about 2.8–9% among cardiac
tumours, one understands the rarity of this condition.1,7,8
The modern non-invasive imaging methods for detection of car-
diac tumours have modified the approach to their diagnosis and man-
agement by allowing early and accurate detection.9
A comprehensive literature review by Weidong et al.1 of 200 car-
diac haemangiomas reported across all ages, and confirmed on histo-
pathology following surgical resection found only 13 cases diagnosed
in foetal life and 17 cases diagnosed between 0 and 9 years of age. All
Figure 6 Case 2: cardiac magnetic resonance imaging at 2 months
of age showing a mass measuring 28 mm in diameter isointense on
T1 sequence. The star is marking the mass.
Figure 7 Case 2: T2-cardiac magnetic resonance imaging se-
quence showing a hyperintense and highly vascular mass with inflow
voids. The star is marking the mass.
Figure 8 Case 2: cardiac magnetic resonance imaging at 8 months

















































































































































other cardiac haemangiomas were diagnosed in adulthood, making
infantile haemangiomas extremely rare. Microscopically, haemangio-
mas in general are usually divided into cavernous (haemangiomas
composed of multiple, dilated, and thin-walled vessels), capillary
(smaller capillary-like vessels), and arteriovenous types (dysplastic
malformed arteries and veins). Cardiac haemangiomas often combine
features of more than one subtype. Weidong et al. concluded that
the cavernous type (51.1%) was the predominant subtype.
In the cases described in the literature thus far, treatment was ei-
ther surgical resection or conservative follow-up and management of
side-effects. Although cardiac haemangiomas are non-malignant
tumours, they are frequently associated with adverse events caused
by their size and location (obstructive phenomena, arrhythmias, syn-
cope, angina, shortness of breath, and other cardiac tumour manifes-
tations). They can also present with manifestations related to their
nature, such as bleeding, which can lead to pericardial effusion if the
location is in the pericardium. Their nature as vascular tumours also
makes their resection more challenging due to the increased risk of
bleeding.
Since the accidental discovery of propranolol’s effectiveness in the
treatment of infantile haemangiomas in 2008, the treatment of mainly
skin lesions has been totally revolutionized.10 Propranolol is a non-
selective b-adrenergic receptor blocker. B-adrenergic receptors,
including b1-adrenergic and b2-adrenergic receptors, are G-protein
coupled receptors on endothelial cells that cause vasodilation, as well
as overexpression of proangiogenic factors including VEGF and basic
growth factor of fibroblasts (bFGF). The mechanism of action of pro-
pranolol in the treatment of infantile haemangiomas is still not entire-
ly explained, but is thought to involve multiple processes including
vasoconstriction, inhibition of angiogenesis and induction of apop-
tosis.11–14 These effects are grouped into short-term, mid-term, and
long-term effects.11 The initial rapid involution of infantile haemangio-
mas during the first 1–3 days of propranolol treatment are likely
related to its immediate vasoconstrictive effects and decrease in
vasodilatory nitric oxide leading to softening.11,12 Mid-term effects
are mediated through inhibition of angiogenesis leading to progres-
sive reduction in size due to a decrease in proangiogenic factors
including VEGF, bFGF, and matrix metalloproteinases 2 and 9.11
Long-term effects are thought to be due to induction of apoptosis in
endothelial cells.11,15
Numerous studies regarding propranolol’s effectiveness and safety
profile have been published since. In a recent literature review,2
Hagen et al. acknowledge the positive results of treatment with pro-
pranolol and report an acceptable side-effect profile, especially in
healthy infants. Certain adverse effects are widely recognized, as
attributed to its non-selective b-blocker activity. These include hypo-
glycaemia, hypotension, bradycardia, bronchospasm, sleep disturban-
ces, and diarrhoea.10,16–18
To our knowledge, our described cases represent the 1st two
cases in the literature where propranolol was tried and successfully
treated cardiac haemangiomas with complete resolution of the car-
diac tumours. Furthermore, propranolol—along with steroid ther-
apy—was also effective in dealing with the sequelae of Kasabach–
Merritt syndrome in our 1st case, although this is not the standard
and has only been demonstrated in a few case reports of Kasabach–
Merritt syndrome with extracardiac haemangiomas.19
The authors believe that infantile haemagiomas of the skin and the
heart could have similar characteristics and behaviour. It is obviously
difficult to accurately diagnose a haemangioma of the heart; however,
the vascular characteristics of the tumour on MRI and echocardio-
gram, as well as the typical behaviour of rapid increase in size in the
1st weeks or months of life, should flag this up as a possible diagnosis.
The authors’ recommendation is that due to the low rate of side-
effects of treatment with propranolol, the very quick response to
treatment reported in our two cases of cardiac haemangiomas, simi-
lar to that of infantile haemangiomas of the skin, and the obvious risk
of complications from surgical resection, all neonates and infants with
cardiac tumours that resemble haemangiomas should receive a trial
treatment with propranolol starting conservatively at 1 mg/kg/day in
three divided doses and titrated up to 3 mg/kg/day in two to three
divided doses for at least 4 weeks before considering surgical alterna-
tives. If there is a response, the treatment should continue for the 1st
year of life with subsequent tapering under continuous follow-up. As
expected, there is no available data on recurrence of cardiac haeman-
giomas after discontinuation of propranolol therapy. Our two cases
have been followed-up for 2 and 4 years, respectively and there has
been no recurrence evident on echocardiography or MRI.
Extrapolating data from case series on recurrence of haemangiomas
of the skin, we could be looking at a 25% chance of recurrence; how-
ever, this number is affected by different variables like sex (more
common in females), age at discontinuation of therapy (more com-
mon when it was stopped before 9 months of age comparing to
12–15 months of age) as well as factors concerning the tumours, like
location and special tumour characteristics.20 Mean age at initial re-
bound was 17 months,20 which would justify a more close follow-up
during the 1st months after discontinuation with echocardiograms
and MRI.
Conclusion
Despite the rarity of cardiac haemangiomas, their presentation and
complications could be dramatic with side-effects spanning from intra-
cardiac space occupying phenomena to Kasabach–Merritt syndrome.
Propranolol therapy, having been established for long now in the treat-
ment of skin haemangiomas, should also be considered in cases of car-
diac haemangiomas, particularly in the neonatal and infantile population.
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Supplementary material is available at European Heart Journal - Case
Reports online.
Slide sets: A fully edited slide set detailing this case and suitable for
local presentation is available online as Supplementary data.
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